Literature DB >> 16149909

Efficient delivery of RNA interference effectors via in vitro-packaged SV40 pseudovirions.

Chava Kimchi-Sarfaty1, Scott Brittain, Susan Garfield, Natasha J Caplen, Qingquan Tang, Michael M Gottesman.   

Abstract

Previously we have shown that in vitro-packaged simian virus 40 (SV40) pseudovirions (IVPs) are an efficient delivery system for supercoiled DNA plasmids of up to 17.7 kb, with or without SV40 sequences. RNA interference (RNAi) is a naturally occurring gene-silencing mechanism mediated by small double-stranded RNA molecules (small interfering RNAs, siRNAs). This study demonstrates the first use of SV40 pseudovirions to deliver into human cells both principal types of RNAi effector molecules: plasmid-expressed short hairpin RNAs (shRNAs) and synthetic siRNAs. We first established the ability of human lymphoblastoid cells to support RNAi, using sequential transduction of .45 cells with packaged plasmid DNA expressing the green fluorescent protein (IVP-GFP), and an shRNA corresponding to the GFP (IVP-shGFP). SV40 mediates DNA transfer of nucleic acid to the cytoplasm, where RNAi-associated cleavage of mRNA principally occurs. Using SV40 pseudovirions, siRNA-mediated RNAi was observed in both .45 cells, after sequential transduction of IVP-GFP and IVP-packaged siRNAs corresponding to GFP (IVP-siGFP), and in HeLa cells stably expressing a GFP transduced with IVP-siGFP. Our findings indicate that SV40 pseudovirions may be a useful addition to the delivery systems currently being used for the transfer of RNAi effector molecules.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16149909      PMCID: PMC1618762          DOI: 10.1089/hum.2005.16.1110

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  15 in total

1.  Targeting CCR5 with siRNAs: using recombinant SV40-derived vectors to protect macrophages and microglia from R5-tropic HIV.

Authors:  Pierre Cordelier; Barry Morse; David S Strayer
Journal:  Oligonucleotides       Date:  2003

Review 2.  The ins and outs of RNAi in mammalian cells.

Authors:  M Banan; N Puri
Journal:  Curr Pharm Biotechnol       Date:  2004-10       Impact factor: 2.837

Review 3.  Assembly and function of RNA silencing complexes.

Authors:  Erik J Sontheimer
Journal:  Nat Rev Mol Cell Biol       Date:  2005-02       Impact factor: 94.444

Review 4.  Short interfering RNAs as a tool for cancer gene therapy.

Authors:  Marta Izquierdo
Journal:  Cancer Gene Ther       Date:  2005-03       Impact factor: 5.987

5.  Self-assembly and protein-protein interactions between the SV40 capsid proteins produced in insect cells.

Authors:  Z Sandalon; A Oppenheim
Journal:  Virology       Date:  1997-10-27       Impact factor: 3.616

6.  High cloning capacity of in vitro packaged SV40 vectors with no SV40 virus sequences.

Authors:  Chava Kimchi-Sarfaty; Mili Arora; Ziv Sandalon; Ariella Oppenheim; Michael M Gottesman
Journal:  Hum Gene Ther       Date:  2003-01-20       Impact factor: 5.695

7.  Single-stranded antisense siRNAs guide target RNA cleavage in RNAi.

Authors:  Javier Martinez; Agnieszka Patkaniowska; Henning Urlaub; Reinhard Lührmann; Thomas Tuschl
Journal:  Cell       Date:  2002-09-06       Impact factor: 41.582

8.  Transduction of multiple cell types using improved conditions for gene delivery and expression of SV40 pseudovirions packaged in vitro.

Authors:  Chava Kimchi-Sarfaty; Nathan S Alexander; Scott Brittain; Saadia Ali; Michael M Gottesman
Journal:  Biotechniques       Date:  2004-08       Impact factor: 1.993

9.  A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA.

Authors:  Gustavo Tiscornia; Oded Singer; Masahito Ikawa; Inder M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

Review 10.  SV40 pseudovirions as highly efficient vectors for gene transfer and their potential application in cancer therapy.

Authors:  Chava Kimchi-Sarfaty; Michael M Gottesman
Journal:  Curr Pharm Biotechnol       Date:  2004-10       Impact factor: 2.837

View more
  9 in total

Review 1.  Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery.

Authors:  Byungji Kim; Ji-Ho Park; Michael J Sailor
Journal:  Adv Mater       Date:  2019-09-30       Impact factor: 30.849

2.  Pseudovirions as vehicles for the delivery of siRNA.

Authors:  Paul E Lund; Ryan C Hunt; Michael M Gottesman; Chava Kimchi-Sarfaty
Journal:  Pharm Res       Date:  2009-12-09       Impact factor: 4.200

3.  Effect of dsDNA on the Assembly Pathway and Mechanical Strength of SV40 VP1 Virus-like Particles.

Authors:  Mariska G M van Rosmalen; Chenglei Li; Adam Zlotnick; Gijs J L Wuite; Wouter H Roos
Journal:  Biophys J       Date:  2018-09-13       Impact factor: 4.033

4.  Inhibition of multidrug resistance by SV40 pseudovirion delivery of an antigene peptide nucleic acid (PNA) in cultured cells.

Authors:  Benjamin Macadangdang; Ning Zhang; Paul E Lund; Andrew H Marple; Mitsunori Okabe; Michael M Gottesman; Daniel H Appella; Chava Kimchi-Sarfaty
Journal:  PLoS One       Date:  2011-03-22       Impact factor: 3.240

5.  Targeted delivery of siRNA.

Authors:  Sabrina Oliveira; Gert Storm; Raymond M Schiffelers
Journal:  J Biomed Biotechnol       Date:  2006

Review 6.  Engineered biological entities for drug delivery and gene therapy protein nanoparticles.

Authors:  Joan Domingo-Espín; Ugutz Unzueta; Paolo Saccardo; Escarlata Rodríguez-Carmona; José Luís Corchero; Esther Vázquez; Neus Ferrer-Miralles
Journal:  Prog Mol Biol Transl Sci       Date:  2011       Impact factor: 3.622

Review 7.  Therapeutic RNA?

Authors:  B W J Mahy
Journal:  Rev Med Virol       Date:  2005 Nov-Dec       Impact factor: 6.989

Review 8.  Progress towards in vivo use of siRNAs.

Authors:  Mark A Behlke
Journal:  Mol Ther       Date:  2006-02-14       Impact factor: 11.454

Review 9.  Therapeutic opportunities of small interfering RNA.

Authors:  Bhoomika R Goyal; Mayur M Patel; Mithil K Soni; Shraddha V Bhadada
Journal:  Fundam Clin Pharmacol       Date:  2009-08       Impact factor: 2.748

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.